$1 billion to develop innovative protein degradation therapy AbbVie has reached a research and development partnership

In the field of drug development, "non-drug" means that the protein surface does not have a place for small molecule compounds to bind, so small molecule drugs cannot be targeted.
currently, up to 90% of the 20,000 or so proteins in the human body fall into this type.
these "non-drugable" proteins may appear in temporary "pockets" when encountering other binding proteins in cells, but they exist for a short period of time and disappear after the protein has functioned.
Frontier Medicines' chemical proteomics platform was able to use covalent probes to detect short-lived binding points on proteins.
, the technology platform is designed with co-price compounds capable of targeting 50 percent of the "non-drugable" protein group.
the company is also developing targeted protein degradation technology based on E3 ubibin connective enzymes, which, in combination with these co-priced compounds, can degrade "non-drugable" targets into the proteases of cells.
the company topped the biotech mammoth of the year list last year.
agreement, AbbVie will pay Frontier $55 million in upfront payments, as well as part of frontier's preclinical development costs.
will work together to advance scientific discovery and preclinical development projects for E3 connective enzymes, immunology and oncology targets.
AbbVie will be responsible for the subsequent global development and commercialization of the project after successfully reaching the intended preclinical development phase.
Frontier is eligible for milestone payments that could exceed $1 billion.
: abbVie and Frontier Medicines Company Global Partnership to Discover and Develop Novel Therapies and E3 DegradErs Against Difficult-to-Drug Targets. Retrieved December 2, 2020, from。